Danaher Corporation $DHR Stock Position Lessened by Banco Bilbao Vizcaya Argentaria S.A.

Banco Bilbao Vizcaya Argentaria S.A. trimmed its holdings in shares of Danaher Corporation (NYSE:DHR) by 4.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 44,198 shares of the conglomerate’s stock after selling 1,918 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Danaher were worth $8,737,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Red Tortoise LLC increased its stake in Danaher by 175.0% during the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock valued at $30,000 after buying an additional 98 shares during the period. Ramirez Asset Management Inc. acquired a new stake in shares of Danaher in the 2nd quarter worth approximately $40,000. Costello Asset Management INC bought a new position in shares of Danaher in the first quarter valued at approximately $41,000. Mowery & Schoenfeld Wealth Management LLC increased its stake in shares of Danaher by 53.8% during the first quarter. Mowery & Schoenfeld Wealth Management LLC now owns 203 shares of the conglomerate’s stock valued at $42,000 after acquiring an additional 71 shares during the period. Finally, Strengthening Families & Communities LLC raised its holdings in Danaher by 81.4% during the first quarter. Strengthening Families & Communities LLC now owns 254 shares of the conglomerate’s stock worth $52,000 after purchasing an additional 114 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Trading Up 0.0%

NYSE:DHR opened at $221.25 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $258.23. The firm has a market capitalization of $156.28 billion, a price-to-earnings ratio of 45.62, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81. The stock has a fifty day simple moving average of $205.63 and a 200 day simple moving average of $201.09.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $6 billion. During the same quarter in the previous year, the company earned $1.71 EPS. The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. Sell-side analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Friday, September 26th were given a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Friday, September 26th. Danaher’s dividend payout ratio is 26.39%.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 2,778 shares of Danaher stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Brian W. Ellis sold 21,776 shares of the stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the sale, the senior vice president owned 14,553 shares of the company’s stock, valued at $3,190,454.19. The trade was a 59.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 29,728 shares of company stock valued at $6,448,990. Company insiders own 11.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Robert W. Baird set a $247.00 price target on Danaher in a research note on Wednesday, October 22nd. Wall Street Zen cut Danaher from a “buy” rating to a “hold” rating in a research note on Monday, November 10th. Evercore ISI boosted their price target on shares of Danaher from $226.00 to $245.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Rothschild Redb downgraded shares of Danaher from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 8th. Finally, Wells Fargo & Company reaffirmed a “positive” rating on shares of Danaher in a research note on Thursday, October 23rd. Eighteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $243.39.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.